4DMEDICAL Ltd (4dx) Logo


___:___ · AUD

4DX Chart

4DX's Principal Activity is the medical imaging software and hardware provider.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -11.90%
vs ASX 200 (1yr) -25.32%


Market Capitalisation
ASX Rank 563 of 2,295
Sector Rank 41 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies NXS / MVF / ARX
EPS -$0.05
DPS $0.00
NTA per share $0.00

Broker Consensus

4DX is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Company Overview

4DMedical Limited (4DX) is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The company is based in Melbourne, Australia and Los Angeles, USA.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Melbourne VIC 3004
Website www.4dmedical.com
Registry Link Market Services
Auditor PKF Melbourne Audit & Assurance Pty Ltd
Date Listed 7 Aug 2020

Upcoming Calendar (Forecasted)

Date Event
27/08/2021 Report (Prelim)
23/09/2021 Report (Annual)
24/02/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Bruce Rathie Non-Executive Chairman,Non-Executive Director Dec 2019 Director Bio icon

Mr Bruce Rathie

Non-Executive Chairman,Non-Executive Director

Mr Rathie is Non-Executive Directors nearly 20 years standing having completed prior careers in law and finance. His legal career included being a partner of a private law firm and then Senior Corporate Counsel to Robert Holmes a Court's Bell Resources Limited in the 1980's. After completing his MBA in Switzerland, he went into investment banking in 1986 which took him to New York for 3 years returning to Sydney in 1990. He spent the 1990's as an investment banker in Sydney, the last 5 of which as Director Investment Banking and Head of the Industrial Franchise Group at Salomon Brothers and then Salomon Smith Barney where he lead the firm's joint lead manager roles in the privatisations or IPOs of Qantas, Commonwealth Bank and Telstra amongst other major transactions of the day. Bruce has been a Director since 2000 in roles with ASX listed and unlisted companies mainly in the financial services, biotechnology and technology sectors. He is currently a Non-Executive Director of ASX 200 PolyNovo Limited, Capricorn Society Limited, ASX listed Netlinkz Limited and Australian Meat Processors Corporation Limited. He is also Chair of Capricorn Mutual Limited and 4DMedical. Previously, he has been a Non-Executive Director of ASX listed companies Compumedics Limited, Anteo Diagnostics Limited (Chair), USCOM Limited, Mungana Goldmines Limited and Datadot Technology Limited (Chair). He also served as an inaugural CSIRO nominated Non-Executive Director of Polynovo Biomaterials Pty Ltd when the Polynovo technology was first spun out of the CSIRO in 2004, as with several other CSIRO technology commercialisations and served as Chair of a number of these vehicles.

Ms Lilian (Lil) Bianchi Non-Executive Director Dec 2019 Director Bio icon

Ms Lilian (Lil) Bianchi

Non-Executive Director

Ms Bianchi has experience in technology products and business transformations. She has participated in business transformations for US listed technology companies and risk collaborations across financial risk modelling, climate science and primary industry productivity models. She is an experienced contributor to business transformations for US-listed technology companies with technology product knowledge in AI and SaaS offerings and has international experience in the US, Australia, India, Singapore, UK, France, Germany, New Zealand, Italy and Spain. Lil's experience lies in her CEO, board, and senior executive roles in financial services, global listed tech corporations, tech start-ups, tier 1 management consultancies, public sector organisations, and international research operations. Lil is Chair of the Risk Committee.

Mr John Andrew Livingston Non-Executive Director Mar 2018 Director Bio icon

Mr John Andrew Livingston

Non-Executive Director

Mr Livingston was previously one of the founding partners of Lake Imaging, subsequently becoming part of Integral Diagnostics Ltd., where John was CEO and Managing Director. John was awarded the AGFA International Award for Development of Digital Imaging Solutions in 2005. He has lectured in Australia and abroad on the digital radiology environment. John has commercial experience, having worked with the team at Lake Imaging and later Integral Diagnostics through acquisitions and the establishment of Greenfield facilities across Australia. During his career at Integral Diagnostics, John lead the group through private equity investment with Advent Partners in 2014 and in 2015 John worked with Advent to list Integral Diagnostics on the ASX. John is a former director of VicWest Community Telco and United Way, a current director at Comrad Medical Systems and Ballarat Clarendon College (Chair).

Ms Lusia Halina Guthrie Non-Executive Director Dec 2017 Director Bio icon

Ms Lusia Halina Guthrie

Non-Executive Director

Ms Guthrie has over 35 years in the pharmaceutical and bioscience industries. She started her career as a Medical Laboratory Scientist before joining the Manufacturing Division of pharmaceutical company FH Faulding & Co (now Mayne Pharma). Lusia then went on to co-found medical technology innovation company LBT Innovations Limited (ASX:LBT) where she was Chief Executive Officer and Managing Director until 2016. Lusia has worked in the Australian life sciences sector through various engagements including: Chair of BioMelbourne Network; Chair of the Medical Device Partnering Program in Victoria; and Chair Australian Lung Health Initiative. She is also a member of the Innovation Taskforce, an initiative of the Victorian Government Minister for Jobs, Innovation and Trade. Lusia also serves on several advisory boards: Medicines Manufacturing Innovation Centre at Monash University; Australian Institute for Machine Learning at the University of Adelaide; and Australian Regenerative Medicine Institute. Lusia is a member of the Risk Committee.

Mr Julian Bernard Kingsley Sutton Non-Executive Director Sep 2017 Director Bio icon

Mr Julian Bernard Kingsley Sutton

Non-Executive Director

Mr Sutton started his career in 1995 as an actuarial analyst for Towers Perrin in Melbourne where he consulted to some of Australia's superannuation funds. He later transferred with Towers Perrin to Brussels and then to London, where he worked mainly in an asset consulting capacity. In 2002, Julian joined Credit Suisse Asset Management in London as an assistant portfolio manager in their Multi-Manager team. In 2004, Julian joined Schroders Investment Management as a Senior Portfolio Manager in the Multi-Asset team, responsible for the management of a suite of investment funds with assets under management. After seven years with Schroders, Julian returned to Australia with entrepreneurial ambitions. Currently, Julian is responsible for the sales and marketing function of Brown Advisory in Australia.

Dr Robert Alan Figlin Non-Executive Director Dec 2016 Director Bio icon

Dr Robert Alan Figlin

Non-Executive Director

Dr Figlin is a Professor of Medicine and Biomedical Sciences and the Steven Spielberg Family Chair in Hematology-Oncology, Director of the Division of Hematology-Oncology, Deputy Director of the Samuel Oschin Comprehensive Cancer Institute and Deputy Director of Integrated Oncology at Cedars-Sinai Medical Center in Los Angeles, California. He completed his residency and chief residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematology/oncology at the David Geffen School of Medicine at University of California, Los Angeles (UCLA). He is an Emeritus Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA. Robert serves as Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He has authored over 350 peer reviewed articles, more than 70 book chapters, and has published, as Editor, multiple books on kidney cancer. He is the Editor of the Springer Science book entitled, Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets.

Mr Heath Norman Lee Chief Financial Officer,Executive Director Jul 2016 Director Bio icon

Mr Heath Norman Lee

Chief Financial Officer,Executive Director

Mr Lee gained his Chartered Accountant qualification working with KPMG before moving into investment banking with BZW (Barclays Bank) which was later acquired by ABN AMRO. As a merger and acquisitions executive, Heath advised the Federal Government of Australia on Phase 1 & 2 privatisation of Australia's airports and CSR on its demerger of Rinker Materials. With experience advising companies in relation to trade sales, mergers & acquisitions and company strategy, Heath left ABN AMRO to launch his own business. Over a period of 9 years, as founder and CEO, Heath built OCIS from a startup contact centre and market research company to a business operating in Australia, New Zealand and Fiji servicing clients such as Optus, The Nielsen Company, Seek.com, Virgin Mobile and the New Zealand Government before the business was sold in 2013.

Dr Andreas Fouras Chief Executive Officer,Managing Director Dec 2012 Director Bio icon

Dr Andreas Fouras

Chief Executive Officer,Managing Director

Dr Fouras started his career in academic research studying experimental fluid dynamics in the Department of Mechanical and Aerospace Engineering at Monash University in Melbourne, Australia. His early research in wind tunnel quantification placed him as a young leader in the area of imaging (within fluid dynamics) developing a number of new approaches to the imaging of gas and liquid flow. He held the position of Professor and Director of the Laboratory for Dynamic Imaging. Andreas was recognised by various awards from a range of research bodies including the National Health and Medical Research Council and the American Asthma Foundation. Andreas was able to apply concept to clinical use through the development of XV Technology, measuring airflow within the breathing lungs, at every stage of the breath, with both high spatial and temporal resolution at very low dose. Andreas' research has been documented in over 100 peer reviewed publications and over 40 patents and patent applications. Andreas founded 4DMedical in December 2012. He received Australian Davos Connection Australian Leadership Award (2013).

Ms Charlene Shia-Ying Stahr Company Secretary N/A

Director Transactions

4DX directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
07/04/21 Lilian (Lil) Bianchi Issued 3,306 $1.55 $5,124 Participation in share purchase plan
07/04/21 Lusia Guthrie Issued 2,409 $1.55 $3,733 Participation in share purchase plan
07/04/21 Bruce Rathie Issued 9,638 $1.55 $14,938 Participation in share purchase plan

Director Interests

The current holdings of 4DX directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Lilian (Lil) Bianchi 07/04/2021 N/A 53,306 N/A N/A
Lusia Guthrie 07/04/2021 N/A 207,409 N/A N/A
Bruce Rathie 07/04/2021 N/A 509,638 N/A N/A
John Livingston 07/03/2018 N/A 1,925,352 N/A N/A
Julian Sutton 15/09/2017 297,786 183,014 6,205,162 N/A
Robert Figlin 09/12/2016 519,943 N/A N/A N/A
Heath Lee 01/07/2016 N/A 1,057,682 490,160 N/A
Andreas Fouras 17/12/2012 N/A 64,838,000 6,036,693 N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Aug 7, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Velocimetry Consulting Pty Ltd (Fouras Family A/C) 64,838,000 24.49%
HSBC Custody Nominees (Australia) Limited (i) 10,136,428 3.83%
National Nominees Limited 9,076,064 3.43%
Pacific Custodins Pty Limited (Employee Share TST A/C) 7,677,919 2.90%
Ryder Innovation Fund Lp 6,290,475 2.38%
Mainstream Fund Services Pty Ltd 5,766,269 2.18%
CS Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C) 5,239,727 1.98%
SSD Nominees Pty Ltd (SSD Family A/C) 5,000,000 1.89%
Jordan Blair Thurgood & Phillip Charles Thurgood 5,000,000 1.89%
J P Morgan Nominees Australia Pty Limited 4,816,959 1.82%
BNP Paribas Noms Pty Ltd (DRP) (i) 3,934,191 1.49%
Citicorp Nominees Pty Limited 2,653,144 1.00%
Alex Petrou & Christine Petrou (Petrou Family Super Fund A/C) 2,462,000 0.93%
HSBC Custody Nominees Australia) Limited - A/C 2 (iii) 2,157,535 0.81%
Endless Smiles Pty Ltd (CMBK Family A/C) 2,100,000 0.79%
Dean Egan 1,904,500 0.72%
BNP Paribas Noms Pty Ltd (DRP) (ii) 1,572,619 0.59%
HSBC Custody Nominees Australia) Limited-Gsco Eca (ii) 1,506,850 0.57%
Merrill Lynch (Australia) Nominees Pty Ltd 1,467,778 0.55%
Morgan Stanley Australia Securities (Nominee) Pty Limited (No 1 Account) 1,369,864 0.52%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 4 35 621 703 256 1,619

Substantial Shareholders

No Substantial Shareholders for 4DX in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
10-03-21 Perennial Value Management Limited 16,128,334 -- 5.35
07-08-20 Perennial Value Management Limited 14,526,356 -- 5.49

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
07-04-21 Velocimetry Consulting Pty Ltd 7,251,079 50.82 43.2
09-12-20 Perennial Value Management Limited 14,526,356 5.49 --

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
4DX Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.